Company
Oxford BioTherapeutics Ltd
Oxford BioTherapeutics Ltd has 1 drug tracked on RxWires: 1 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| OBT076, a CD205-directed antibody-drug conjugate | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Oxford BioTherapeutics Ltd on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.